Asia-Pacific bladder cancer market was valued at $1.3 billion in 2025 and is projected to reach $2.3 billion by 2035, growing at a CAGR of 6.0% during the forecast period (2026–2035). The Asia Pacific bladder cancer market is witnessing structural shifts driven by rising disease incidence and growing adoption of advanced diagnostic technologies. Increasing awareness, improved reporting systems, and expanded oncology infrastructure are contributing to more accurate case identification across major regional economies. Bladder cancer cases across the Asia Pacific region are rising at a significant rate, reflecting a growing clinical challenge. In 2023, China alone accounted for over 92,883 new cases of bladder cancer, highlighting the substantial scale of the disease in the country. Meanwhile, according to the Korean National Cancer Registry, South Korea reported more than 5,169 new cases in 2024, with approximately 1,821 related fatalities, underscoring the ongoing clinical burden posed by the disease in the region.
Browse the full report description of “Asia-Pacific Bladder Cancer Market Size, Share & Trends Analysis Report by Cancer Type (Transitional Cell Bladder Cancer/ Urothelial Carcinoma, Squamous Cell Bladder Cancer, Adenocarcinoma, and Other Rare Types) By Diagnosis Method (Cystoscopy, Biopsy, Urinalysis, Urine Cytology, Intravenous Pyelogram (IVP), and Other) By Therapy (Chemotherapy, Immunotherapy, Radiation Therapy, Surgery, and Other), 2026–2035)” at https://www.omrglobal.com/industry-reports/asia-pacific-bladder-cancer-market
In response to these trends, the development of innovative medical devices such as imaging systems and genetic test reagents that assist in diagnosing bladder cancer, is gaining relevance in the regional market. These diagnostic tools are designed to detect specific genetic mutations or molecular biomarkers from urine or tissue samples, supporting earlier and more precise identification of malignancy. Compared with conventional diagnostic pathways, molecular-based assays may contribute to improved risk stratification and recurrence monitoring. The integration of such technologies into routine clinical practice is gradually expanding, supported by advancements in laboratory infrastructure and regulatory frameworks across Asia Pacific. For instance, in January 2026, South Korea’s Ministry of Food and Drug Safety approved a domestically developed genetic test reagent as a newly developed medical device for diagnosing bladder cancer. The test targets 40-year-old patients with hematuria and suspected bladder cancer, detecting methylated PENK in urine using real-time polymerase chain reaction. Authorities noted that the device shows improved clinical effectiveness compared with existing diagnostic methods and meets safety standards for patient use. As incidence remains significant in key markets, demand for reliable, minimally invasive diagnostic solutions is expected to remain steady.
Market Leaders and Innovations
The Asia-Pacific bladder cancer market is led by major companies including Merck & Co., Inc., Pfizer Inc., AstraZeneca Plc, Bristol-Myers Squibb Company, and F. Hoffmann-La Roche Ltd., among others. Significant efforts are underway to expand portfolios through regulatory approvals, strategic product launches, and innovative treatment options. Focus is placed on immunotherapies and combination therapies to enhance patient outcomes and address unmet clinical needs across the region.
Market Coverage
Key questions addressed by the report.
Asia-Pacific Bladder Cancer Market Report Segment
Cancer Type
Diagnosis Method
By Therapy
Asia-Pacific Bladder Cancer Market Report Segment by Region
To learn more about this report request a sample copy @ https://www.omrglobal.com/request-sample/asia-pacific-bladder-cancer-market